Islamabad : Pakistan is facing a shortage of the rapid-acting insulin brand Apidra (insulin glulisine, manufactured by Sanofi.
Cause of the Shortage
Manufacturer Upgrades: Health authorities and the Ministry of National Health Services reported to the National Assembly that the German manufacturer temporarily halted or paused international production and shipments due to facility/product upgrades.
• Supply Drop: Local stock availability dropped significantly (with supplies reported to have fallen from around 3,500 kits down to 1,000 kits).
• General Context: Broader pressures—such as currency devaluation and pricing/distribution disputes—have also impacted the availability of various life-saving medicines across Pakistan.
Available Alternatives
Health officials and the Drug Regulatory Authority of Pakistan (DRAP) note that other rapid-acting insulin analogues remain available nationwide:
• NovoRapid (insulin aspart by Novo Nordisk)
• Humalog (insulin lispro by Eli Lilly)
Lawmakers and patient groups have noted that alternative brands can cost 20% or more higher.
Important Safety Precautions
• Do Not Switch on Your Own: Although Apidra, NovoRapid, and Humalog are all rapid-acting insulins, they are not directly interchangeable unit-for-unit in every regimen.
• Consult Your Doctor: Patients currently prescribed Apidra must consult their attending endocrinologist, diabetes specialist, or physician before modifying their dose or switching to an alternative. Changing products requires proper dose titration and blood glucose monitoring.
If you’d like, let me know:
• Who the insulin is for (adult or pediatric patient)
• Whether you need help finding local pharmacies or alternative options in Islamabad or nearby areas.
The reported disruption in the supply of Apidra has raised an urgent question for patients who rely on prescribed insulin to manage their condition. In October 2026, the Ministry of National Health Services and the Drug Regulatory Authority of Pakistan (DRAP) stepped forward to clarify that the problem is strictly limited to insulin glulisine, sold under the brand name Apidra, and does not represent a nationwide shortage of all insulin products. According to health authorities, alternative rapid-acting insulin analogues, including NovoRapid and Humalog, remain available nationwide. However, this administrative clarification does little to ease the immediate anxiety of patients who use Apidra; they have been strongly advised to consult their doctors before changing treatment, as switching insulin formulations requires careful clinical dose adjustment and strict individual monitoring.
The Chasm Between Availability and Access
While the official clarification from health regulators is welcome, it does not remove the steep practical difficulty of finding a seamless, appropriate replacement in real-time. A substitute listed as available on paper is of little practical use if a vulnerable patient cannot physically obtain it or afford it at the pharmacy counter. This disruption highlights a deeper structural crack in the safety net: health authorities must move beyond reactionary press releases and actively publish timely, transparent information about supply chain disruptions. Furthermore, public policy must dictate where affected patients can immediately obtain clinical guidance, and public hospitals must be equipped with dedicated support channels to help patients navigate alternative treatments safely and without bureaucratic delay.
A Broad Public Health Emergency
With an estimated 33 million to 34.5 million people living with diabetes in Pakistan, and more than one million citizens relying directly on daily insulin for survival, continuity of treatment must be treated as a critical matter of public health, not merely a backend supply-chain issue. The economic realities further complicate this crisis, as past data shows that market deregulation can drive up median insulin prices by over 31 per cent, pricing vulnerable households out of life-saving care. When supply chains fracture, local production and alternative brands can only stabilize the market if they are paired with strict public procurement and transparent price monitoring. The government must take absolute responsibility to ensure that patients can easily obtain medical advice and continue their insulin therapy safely, affordably, and completely uninterrupted.